Ochsner Health announced plans to participate as a study site for the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2 (commo…
Ochsner Health announces first enrollment for Phase 2/3 study of vaccine for Covid-19